Dana-Farber Research Supports FDA Approval of Immunotherapy Drug Given After Surgery for Certain Patients With Kidney Cancer
November 19, 2021
November 19, 2021
BOSTON, Nov. 19 (TNSJou) -- The Dana-Farber Cancer Institute issued the following news release:
* * *
Pembrolizumab is the first drug approved as adjuvant therapy for patients with kidney cancer considered at high risk of relapse
* * *
An immunotherapy drug given as a treatment following kidney cancer surgery, whose clinical testing was led by Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, becomes a standard of care in kidney cancer.
* * *
Pembrolizumab is the first drug approved as adjuvant therapy for patients with kidney cancer considered at high risk of relapse
* * *
An immunotherapy drug given as a treatment following kidney cancer surgery, whose clinical testing was led by Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, becomes a standard of care in kidney cancer.